The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Mesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury
Open accessAbstract
Various hepatoxic factors, such as viruses, drugs, lipid deposition, and autoimmune responses, induce acute or chronic liver injury, and 3.5% of all worldwide deaths result from liver cirrhosis, liver failure, or hepatocellular carcinoma. Liver transplantation is currently limited by few liver donors, expensive surgical costs, and severe immune rejection. Cell therapy, including hepatocyte transplantation and stem cell transplantation, has recently become an attractive option to reduce the overall need for liver transplantation and reduce the wait time for patients. Recent studies showed that mesenchymal stem cell (MSC) administration was a promising therapeutic approach for promoting liver regeneration and repairing liver injury by the migration of cells into liver sites, hepatogenic differentiation, immunoregulation, and paracrine mechanisms. MSCs secrete a large number of molecules into the extracellular space, and soluble proteins, free nucleic acids, lipids, and extracellular vesicles (EVs) effectively repair tissue injury in response to fluctuations in physiological states or pathological conditions. Cell-free-based therapies avoid the potential tumorigenicity, rejection of cells, emboli formation, undesired differentiation, and infection transmission of MSC transplantation. In this review, we focus on the potential mechanisms of MSC-based cell-free strategies for attenuating liver injury in various liver diseases. Secretome-mediated paracrine effects participate in the regulation of the hepatic immune microenvironment and promotion of hepatic epithelial repair. We look forward to completely reversing liver injury through an MSC-based cell-free strategy in regenerative medicine in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“newer research has determined their phenomenal plasticity, including their potency to differentiate into hepatocyte-like cells (HLCs)([39, 40]”
From From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy (2025) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
Fitzmaurice, C., Allen, C., Barber, R. M., Barregård, L., Bhutta, Z. A., Brenner, H., Dicker, D., Chimed‐Ochir, O., Dandona, R., Dandona, L., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,318
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426
Routes and mechanisms of extracellular vesicle uptake
Mulcahy, L. A., Pink, R. C., & Carter, D. R. F. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.24641 · Cited by 2,832
Research works printed but not linked: 1
- Michalopoulos GK, DeFrances M. Liver regeneration. Adv Biochem Eng Biotechnol. 2005;93:101–34.
Cited by
Sorted by citations
Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review
Margiana, R., Markov, A. A., Zekiy, A. O., Hamza, M. U., Aldabbagh, K. A. O., Al-Zubaidi, S. H., Hameed, N. M., Ahmad, I., Sivaraman, R., Kzar, H. H., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03054-0 · Cited by 443
Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy
Lin, Y., Yan, M., Bai, Z., Xie, Y., Ren, L., Wei, J., Zhu, D., Wang, H., Liu, Y., Luo, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01636-x · Cited by 125
Li, M., Jiang, Y., Hou, Q., Zhao, Y., Zhong, L., & Fu, X. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02822-2 · Cited by 119
Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential
Liu, P., Mao, Y., Xie, Y., Wei, J., & Yao, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03041-5 · Cited by 82
Molecular Mechanisms and Potential New Therapeutic Drugs for Liver Fibrosis
Wang, F.-D., Zhou, J., & Chen, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.787748 · Cited by 79
Metadata
- Authors
- Hu, C., Zhao, L., Zhang, L., Bao, Q., & Li, L.
- Affiliations
- First Affiliated Hospital Zhejiang University (CN)
- Corresponding author
- Li, Lanjuan
- Venue
- Stem Cell Research & Therapy
- Published
- 2020-09-03
- Volume
- 11
- Issue
- 1
- Pages
- 377-377
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC7469278
- OpenAlex
- W3082320282
- Cited by
- 130
- References
- 103
- Citations by year
- 2026: 7 · 2025: 22 · 2024: 23 · 2023: 35 · 2022: 28 · 2021: 15
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81700553)
- Zhejiang basic public welfare research program (LGF20H030008)
- Independent Fund of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- mesenchymal stem cells, cell-free therapy, liver injury, liver regeneration, extracellular vesicles, secretome, paracrine signaling, hepatocyte transplantation, liver transplantation alternatives, liver cirrhosis, liver failure, hepatocellular carcinoma, immune regulation, hepatic immune microenvironment, hepatocyte differentiation
- MeSH terms
- Extracellular Vesicles, Humans, Liver Diseases, Liver Regeneration, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
